AlkaliDx is a privately-held research & development company focused on a channelopathy form of ADHD. We are developing a novel diagnostic test, an understanding of the genetics, and improved treatments for this disease.

Today, 7% of US children get prescription drugs for Attention Deficit (Attention Deficit Hyperactivity Disorder or ADHD and Attention Deficit Disorder or ADD), mostly in the form of amphetamines. Such amphetamines have been shown to improve focus, but come with side effects and risks of misuse and abuse.

AlkaliDx discoveries offer an alternative benign therapy for the large subgroup of patients with ADHD for whom the anesthetic lidocaine does not work (roughly 10 million in the US and 150 million worldwide), that enables patients to reduce the stimulant dose, or do without them entirely.

AlkaliDx is developing a treatment and companion diagnostic for this subgroup.

Copyright © 2019 AlkaliDx Inc. All rights reserved.